Literature DB >> 30842186

Prognostic Significance of Lymph Node Dissection Along the Upper-third-stomach in Patients With Lower-third Gastric Cancer.

Ryo Saito1, Yoshihiko Kawaguchi1, Hidenori Akaike1, Kensuke Shiraishi1, Suguru Maruyama1, Hiroki Shimizu1, Shinji Furuya1, Naohiro Hosomura1, Hidetake Amemiya1, Hiromichi Kawaida1, Makoto Sudo1, Shingo Inoue1, Hiroshi Kono1, Daisuke Ichikawa2.   

Abstract

BACKGROUND/AIM: The extent of lymph node (LN) dissection is defined according to the type of gastrectomy regardless of tumor location in recent Japanese gastric cancer treatment guidelines. However, lymphatic flow from lower-third stomach mainly drain to supra- and infra-pyloric nodes, as well as to partially lesser curvature nodes along the descending limb of the left gastric artery. In this study, we evaluated the prognostic impact of LN dissection of right paracardial (No. 1) and left greater curvature (No. 4sb) nodes in gastric cancer of lower-third stomach (LGC). PATIENTS AND METHODS: A total of 239 patients with LGC who underwent distal gastrectomy at our hospital were retrospectively analyzed. The therapeutic value index (TVI) of each node was calculated by multiplying the incidence of LN metastasis by the 5-year survival rate of patients with metastasis to each nodal station.
RESULTS: The incidence of No. 1 LN metastasis was 4.5% (positive/negative; 5/110 cases, unknown or no description; 129 cases). The 5-year survival rate of patients with metastasis to the node was 0%, and consequently the TVI of No. 1 LN station was "0". Similarly, the TVI of No. 4sb was found to be "0".
CONCLUSION: Survival benefit of dissection of No. 1 and No. 4sb LNs was presumed to be extremely low, suggesting that dissection of these two LNs could be omitted in LGC patients when undergoing distal gastrectomy. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Gastric cancer; distal gastrectomy; lymph node dissection

Mesh:

Year:  2019        PMID: 30842186     DOI: 10.21873/anticanres.13266

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  miR-299-3p suppresses cell progression and induces apoptosis by downregulating PAX3 in gastric cancer.

Authors:  Zhenfen Wang; Qing Liu; Ping Huang; Guohao Cai
Journal:  Open Life Sci       Date:  2021-03-23       Impact factor: 0.938

2.  Clinical Significance of Metastasis or Micrometastasis to the Lymph Node Along the Superior Mesenteric Vein in Gastric Carcinoma: A Retrospective Analysis.

Authors:  Xing Xu; Guoliang Zheng; Tao Zhang; Yan Zhao; Zhichao Zheng
Journal:  Front Oncol       Date:  2021-07-29       Impact factor: 6.244

3.  Exploring the scope of 4sb and 12a lymph node dissection for cT2-4 lower third gastric cancer: Study protocol for a prospective cohort trial.

Authors:  Haiqiao Zhang; Zhi Zheng; Xiaoye Liu; Jun Cai; Jie Yin; Jun Zhang
Journal:  Front Surg       Date:  2022-07-14

4.  Intranodal delivery of modified docetaxel: Innovative therapeutic method to inhibit tumor cell growth in lymph nodes.

Authors:  Ariunbuyan Sukhbaatar; Shiro Mori; Tetsuya Kodama
Journal:  Cancer Sci       Date:  2022-02-14       Impact factor: 6.716

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.